Table 2.

Comprehensive Diagnostic Scoring System of the International Autoimmune Hepatitis Group

Clinical features	Points	Clinical features	Points
Female	+2	Average alcohol intake (g/day)
		<25	+2
		>60	−2
AP:AST (or ALT) ratio		Histologic findings
<1.5	+2	Interface hepatitis	+3
1.5–3.0	0	Lymphoplasmacytic infiltrate	+1
>3.0	−2	Rosette formation	+1
		Biliary changes	−3
		Other atypical changes	−3
		None of above	−5
Serum globulin or IgG level above ULN		Concurrent immune disease, including celiac disease	+2
>2.0	+3	Other autoantibodies	+2
1.5–2.0	+2	HLA DRB1*03 or DRB1*04	+1
1.0–1.5	+1
<1.0	0
ANA, SMA, or anti-LKM1		Response to corticosteroids
>1:80	+3	Complete	+2
1:80	+2	Relapse after drug withdrawal	+3
1:40	+1
<1:40	0
AMA positive	−4
Hepatitis markers		Aggregate score pretreatment
Positive	−3	Definite autoimmune hepatitis	>15
Negative	+3	Probable autoimmune hepatitis	10–15
Hepatotoxic drug exposure		Aggregate score posttreatment
Positive	−4	Definite autoimmune hepatitis	>17
Negative	+1	Probable autoimmune hepatitis	12–17

AP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IgG, immunoglobulin G; ULN, upper limit of the normal range; HLA, human leukocyte antigen; ANA, antinuclear antibodies; SMA, smooth muscle antibodies; anti-LKM1, antibodies to liver kidney microsome type 1; AMA, antimitochondrial antibodies.

Adapted from Alvarez F, et al. J Hepatol 1999;31:929–938, with permission of Elsevier BV and the European Association for the Study of the Liver.¹⁹